Table 4 Subgroup analysis in DLBCL patients
Outcome | Studies | HR/OR (95%CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|
I2% | P value | ||||
Impact of HCV infection | |||||
Overall survival | 11 | 2.29 (1.85–2.84) | < 0.00001 | 46 | 0.05 |
Progression-free survival | 7 | 1.55 (1.23–1.95) | 0.0002 | 0 | 0.54 |
Overall response rate | 8 | 0.55 (0.42–0.72) | < 0.00001 | 23 | 0.24 |
Hepatic dysfunction | 6 | 5.89 (2.31–15.01) | 0.0002 | 82 | < 0.0001 |
Age of onset | 7 | 1.31 (0.67–2.57) | 0.43 | 70 | 0.003 |
Advanced disease stage | 11 | 1.20 (0.98–1.48) | 0.08 | 14 | 0.31 |
Presence of B symptom | 6 | 1.16 (0.70–1.94) | 0.56 | 59 | 0.03 |
Elevated LDH level | 9 | 1.47 (1.17–1.85) | 0.0009 | 46 | 0.06 |
H-I/H risk | 10 | 1.34 (1.07–1.67) | 0.01 | 0 | 0.48 |
Spleen involvement | 5 | 2.75 (1.92–3.95) | < 0.00001 | 0 | 0.55 |
Liver involvement | 7 | 1.87 (1.22–2.85) | 0.004 | 0 | 0.60 |
Bone marrow involvement | 6 | 1.03 (0.71–1.50) | 0.86 | 17 | 0.31 |
Impact of anti-viral treatment | |||||
Overall survival | 5 | 0.40 (0.24–0.66) | 0.0003 | 37 | 0.18 |
Progression-free survival/disease-free survival | 4 | 0.60 (0.39–0.92) | 0.02 | 41 | 0.17 |